Taxol and platinum chemotherapy in the treatment of pancreatic and jejunal carcinoma

Tl, Cornelison; Jm, Goldberg; Ms, Piver

doi:10.1002/jso.2930590314

Cited by 7 publications

(1 citation statement)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adjuvant chemotherapy is not well‐reported, and no convincing evidence of increased survival with 5‐FU after surgery has been reported (4). A case report from the Roswell Park Cancer Institute showed complete response of stage IV jejunal adenocarcinoma treated with Taxol and platinum chemotherapy after partial resection (11). Unfortunately, this regimen was ineffective in our patient, probably because of the advanced stage at presentation.…”

Section: Discussionmentioning

confidence: 99%

Jejunal Adenocarcinoma: A Rare Cause of Chronic Anemia in Children

Pasternak

Kaistha²

2006

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Jejunal Adenocarcinoma: A Rare Cause of Chronic Anemia in Children

Pasternak

Kaistha²

2006

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Systemic and adjuvant therapy for patients with pancreatic carcinoma

Clark¹,

Glicksman²,

Wanebo³

1996

Cancer

View full text Add to dashboard Cite

BACKGROUND Pancreatic cancer is a highly lethal disease with cc5% of patients surviving 5 years. There is no curative therapy for patients who cannot be surgically resected. Chemotherapy and radiation therapy can provide palliation but have not had a significant impact on 5‐year survival. METHODS Newer approaches for improving the survival of patients with pancreatic cancer integrating chemotherapy, radiation therapy, and surgery are being evaluated. New chemotherapeutic agents (e.g., gemcitabine, camptothecins, taxanes, thymydilate synthase inhibitors, and fluorouracil‐related compounds) are being studied alone and in combination with each other or different agents (e.g., trimetrexate or platinum‐related compounds). RESULTS Increased knowledge about the biology of pancreatic cancer (including high frequency of ras and p53 mutations in neoplastic cells or the expression of a number of growth factor receptors on the cell surface) has lead to preclinical evaluation of novel approaches attempting to specifically target these. These novel approaches include gene therapy, vaccines, and antisense oligonucleotides targeted to genes important for proliferation or survival of pancreatic cancer cells. CONCLUSIONS Continued development of new approaches is needed to improve the treatment and survival of patients with pancreatic cancer. Cancer 1996;78:688‐93.

show abstract

Systemic and adjuvant therapy for patients with pancreatic carcinoma

Clark

Glicksman

Wanebo

1996

Cancer

View full text Add to dashboard Cite

BACKGROUND Pancreatic cancer is a highly lethal disease with; cc5% of patients surviving 5 years. There is no curative therapy for patients who cannot be surgically resected. Chemotherapy and radiation therapy can provide palliation but have not had a significant impact on 5‐year survival. METHODS Newer approaches for improving the survival of patients with pancreatic cancer integrating chemotherapy, radiation therapy, and surgery are being evaluated. New chemotherapeutic agents (e.g., gemcitabine, camptothecins, taxanes, thymydilate synthase inhibitors, and fluorouracil‐related compounds) are being studied alone and in combination with each other or different agents (e.g., trimetrexate or platinum‐related compounds). RESULTS Increased knowledge about the biology of pancreatic cancer (including high frequency of ras and p53 mutations in neoplastic cells or the expression of a number of growth factor receptors on the cell surface) has lead to preclinical evaluation of novel approaches attempting to specifically target these. These novel approaches include gene therapy, vaccines, and antisense oligonucleotides targeted to genes important for proliferation or survival of pancreatic cancer cells. CONCLUSIONS Continued development of new approaches is needed to improve the treatment and survival of patients with pancreatic cancer. Cancer 1996;78:688‐93.

show abstract

Taxol and platinum chemotherapy in the treatment of pancreatic and jejunal carcinoma

Cited by 7 publications

References 6 publications

Jejunal Adenocarcinoma: A Rare Cause of Chronic Anemia in Children

Jejunal Adenocarcinoma: A Rare Cause of Chronic Anemia in Children

Systemic and adjuvant therapy for patients with pancreatic carcinoma

Systemic and adjuvant therapy for patients with pancreatic carcinoma

Contact Info

Product

Resources

About